[{"id":"d42d31da-cd41-476a-aa36-97b674ad2ab1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04657068","created_at":"2021-01-19T20:41:48.099Z","updated_at":"2024-07-02T16:35:11.625Z","phase":"Phase 1/2","brief_title":"A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04657068","lead_sponsor":"Artios Pharma Ltd","biomarkers":" ATM • HRD • BRCA","pipe":" | ","alterations":" HRD • BRCA mutation","tags":["ATM • HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • irinotecan • alnodesertib (ART0380)"],"overall_status":"Recruiting","enrollment":" Enrollment 462","initiation":"Initiation: 12/13/2020","start_date":" 12/13/2020","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-04-03"},{"id":"2471c56a-1098-45bf-8561-632ff4b4c730","acronym":"ARTIST","url":"https://clinicaltrials.gov/study/NCT05798611","created_at":"2023-04-04T16:04:14.159Z","updated_at":"2024-07-02T16:35:24.450Z","phase":"Phase 2","brief_title":"Study of ART0380 in Patients With Biologically Selected Solid Tumors","source_id_and_acronym":"NCT05798611 - ARTIST","lead_sponsor":"Artios Pharma Ltd","biomarkers":" PD-L1 • PD-1","pipe":"","alterations":" ","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e alnodesertib (ART0380)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 09/06/2023","start_date":" 09/06/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-01-05"}]